About zenas biopharma inc - ZBIO
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
ZBIO At a Glance
Zenas BioPharma, Inc.
852 Winter Street
Waltham, Massachusetts 02451
| Phone | 1-857-271-2954 | Revenue | 5.00M | |
| Industry | Biotechnology | Net Income | -156,988,000.00 | |
| Sector | Health Technology | Employees | 130 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ZBIO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 68.458 |
| Price to Book Ratio | 1.095 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.046 |
| Enterprise Value to Sales | -1.513 |
| Total Debt to Enterprise Value | -0.133 |
ZBIO Efficiency
| Revenue/Employee | 38,461.538 |
| Income Per Employee | -1,207,600.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.023 |
ZBIO Liquidity
| Current Ratio | 6.212 |
| Quick Ratio | 6.212 |
| Cash Ratio | 6.124 |
ZBIO Profitability
| Gross Margin | 97.26 |
| Operating Margin | -3,277.76 |
| Pretax Margin | -3,131.18 |
| Net Margin | -3,139.76 |
| Return on Assets | -71.66 |
| Return on Equity | -93.217 |
| Return on Total Capital | -50.082 |
| Return on Invested Capital | -87.801 |
ZBIO Capital Structure
| Total Debt to Total Equity | 0.321 |
| Total Debt to Total Capital | 0.32 |
| Total Debt to Total Assets | 0.271 |
| Long-Term Debt to Equity | 0.07 |
| Long-Term Debt to Total Capital | 0.07 |